AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1056055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 31677292 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (PBC)
Number of subjects: 28
Study 31677292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 28
Study 31677292 — intervention group
Group type: COMPARATOR
Intervention: Passive control (CON)
Number of subjects: 28
Study 31039774 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment
Number of subjects: 180
Study 31039774 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred hands
Number of subjects: 180
Study 31039774 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 180
Study 31039774 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of additional interphalangeal joints
Number of subjects: 180
Study 31039774 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred hand pain
Number of subjects: 180
Study 28024698 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 16)
Number of subjects: 749
Study 28024698 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 27)
Number of subjects: 749
Study 28024698 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 515)
Number of subjects: 749
Study 25933709 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 430
Study 25933709 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 430
Study 24590961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized user fee intervention
Number of subjects: 47
Study 24590961 — intervention group
Group type: EXPERIMENTAL
Intervention: Free services
Number of subjects: 47
Study 24590961 — intervention group
Group type: COMPARATOR
Intervention: Current cost-sharing systems (Control)
Number of subjects: 47
Study 21599945 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic voiding programme
Number of subjects: 780
Study 21599945 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic voiding programme plus supported implementation
Number of subjects: 780
Study 21599945 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 780
Study 19341544 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blood-test ordering
Number of subjects: 325
Study 19341544 — intervention group
Group type: COMPARATOR
Intervention: Postponed blood-test ordering (after 4 weeks)
Number of subjects: 325
Study 19341544 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded test set
Number of subjects: 325
Study 19341544 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited test set
Number of subjects: 325
Study 16958189 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 16958189 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study 12519316 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat OGTT at 10-year follow-up
Number of subjects: 563
Study 12519316 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects without diabetes at baseline (n = 517)
Number of subjects: 563
Study 12519316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of diabetes
Number of subjects: 563
Study 12519316 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of baseline variables
Number of subjects: 563
Study 10852983 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (60 mg/day) alone (group A)
Number of subjects: 14
Study 10852983 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day) combined with cyclical etidronate (group B)
Number of subjects: 14
Study 10852983 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B at day 5
Number of subjects: 14
Study 9612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and gentamicin (Group A)
Number of subjects: 128
Study 9612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and ciprofloxacin (Group B)
Number of subjects: 128
Study 9612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and cefotaxime (Group C)
Number of subjects: 128
Study 9612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole combination
Number of subjects: 128
Study 9612103 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group C
Number of subjects: 128
Study 9612103 — intervention group
Group type: COMPARATOR
Intervention: Comparison among all groups
Number of subjects: 128
Study 8436000 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimline device
Number of subjects: 996
Study 8436000 — intervention group
Group type: COMPARATOR
Intervention: Standard model
Number of subjects: 996
Study 8436000 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time IUD users
Number of subjects: 996
Study 8436000 — intervention group
Group type: COMPARATOR
Intervention: Former users
Number of subjects: 996
Study 3094172 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (single oral dose)
Number of subjects: 75
Study 3094172 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline (two 1.5-g oral doses taken 12 hr apart)
Number of subjects: 75
Study 3094172 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (in penicillinase-producing Neisseria gonorrhoeae group)
Number of subjects: 75
Study 3094172 — intervention group
Group type: COMPARATOR
Intervention: Lymecycline (in penicillinase-producing Neisseria gonorrhoeae group)
Number of subjects: 75
Study 30365202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol (200–1,000 μg)
Number of subjects: 126
Study 30365202 — intervention group
Group type: COMPARATOR
Intervention: Morphine prolonged release (PR) (≤120 mg daily)
Number of subjects: 126
Study 30365202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol and Morphine PR
Number of subjects: 126
Study 28986703 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027 1 mg/h
Number of subjects: 618
Study 28986703 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027 (lower doses)
Number of subjects: 618
Study 26908002 — intervention group
Group type: EXPERIMENTAL
Intervention: dispatcher-assisted compression-only CPR (DACO-CPR)
Number of subjects: 60
Study 26908002 — intervention group
Group type: EXPERIMENTAL
Intervention: dispatcher-assisted full CPR with rescue ventilation (DAF-CPR)
Number of subjects: 60
Study 26908002 — intervention group
Group type: COMPARATOR
Intervention: unassisted CPR (U-CPR)
Number of subjects: 60
Study 24214165 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (30 sessions)
Number of subjects: 32
Study 24214165 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 32
Study 22127229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 1, 3, and 6
Number of subjects: 0
Study 22127229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 3 and 6
Number of subjects: 0
Study 22127229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 1 and 6
Number of subjects: 0
Study 22127229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline and month 6
Number of subjects: 0
Study 22127229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention
Number of subjects: 0
Study 20810311 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24
Study 20810311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRIs (selective noradrenaline reuptake inhibitors)
Number of subjects: 0
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behavior therapy and SSRIs (selective serotonin reuptake inhibitors)
Number of subjects: 0
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding an SSRI, an SNRI, or an atypical antipsychotic to an SSRI
Number of subjects: 0
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 17492582 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRIs
Number of subjects: 0
Study 12633543 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor captopril
Number of subjects: 298
Study 12633543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 10687671 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 272
Study 10687671 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 272
Study 10687671 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 10 mg
Number of subjects: 272
Study 9181900 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg p.o. daily for six months
Number of subjects: 62
Study 9181900 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg p.o. daily for fourteen days, then reduced to 10 mg for a total treatment period of six months
Number of subjects: 62
Study 8398713 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg qid for 5 days with each course of chemotherapy)
Number of subjects: 226
Study 8398713 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy without verapamil)
Number of subjects: 226
Study 8398713 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 226
Study 3299394 — intervention group
Group type: COMPARATOR
Intervention: ferrous sulphate (100 mg/day)
Number of subjects: 54
Study 3299394 — intervention group
Group type: EXPERIMENTAL
Intervention: ferritin (80 mg/day as Fe3+)
Number of subjects: 54
Study 3299394 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of ferritin (80 mg Fe3+/day), folinic acid and vitamin B12 coenzyme
Number of subjects: 54
Study 30290801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 2475
Study 30290801 — intervention group
Group type: COMPARATOR
Intervention: Other ICS
Number of subjects: 2475
Study 30290801 — intervention group
Group type: COMPARATOR
Intervention: No ICS
Number of subjects: 2475
Study 25772478 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention for 12 weeks
Number of subjects: 0
Study 24851692 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rt-PA with catheter-directed thrombolysis
Number of subjects: 84
Study 24851692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rt-PA with catheter-directed thrombolysis
Number of subjects: 84
Study 24851692 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study 22480663 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg administered 1 hour before each exposure session
Number of subjects: 67
Study 22480663 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour before each exposure session
Number of subjects: 67
Study 20591781 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable resin-based composite restoration
Number of subjects: 20
Study 19064843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound biomicroscopy (UBM) before and after laser iridotomy for newly diagnosed PACG and APAC patients; UBM at enrollment for treated PACG patients.
Number of subjects: 82
Study 15789288 — intervention group
Group type: EXPERIMENTAL
Intervention: IRES-3
Number of subjects: 453
Study 12865480 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally oriented endurance and resistance exercise training (32 weeks, 5 days a week, 2 hours per day)
Number of subjects: 190
Study 12865480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 190
Study 10510162 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 micromol min‐1 N‐monomethyl L‐arginine (L‐NMMA)
Number of subjects: 10
Study 10510162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8787171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (new immunosuppressive drug)
Number of subjects: 277
Study 8787171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 2005075 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168
Study 2005075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study 2005075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study 6404577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (200 mg t.i.d.)
Number of subjects: 20
Study 6404577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30578459 — intervention group
Group type: EXPERIMENTAL
Intervention: High FORTA score (cut-off 3)
Number of subjects: 409
Study 27943391 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprogram group (n = 52, 16%)
Number of subjects: 331
Study 27943391 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet group (n = 51, 15%)
Number of subjects: 331
Study 27943391 — intervention group
Group type: EXPERIMENTAL
Intervention: No change group (n = 228, 69%)
Number of subjects: 331
Study 27943391 — intervention group
Group type: COMPARATOR
Intervention: Thoracic cases
Number of subjects: 331
Study 27943391 — intervention group
Group type: COMPARATOR
Intervention: Head/neck cases
Number of subjects: 331
Study 27943391 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity cases
Number of subjects: 331
Study 27943391 — intervention group
Group type: COMPARATOR
Intervention: Abdominal cases above iliac crest
Number of subjects: 331
Study 27943391 — intervention group
Group type: COMPARATOR
Intervention: Procedures below iliac crest
Number of subjects: 331
Study 26524699 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week CCR based on Nordic walking training (five times weekly) at 40-70% of maximal heart rate
Number of subjects: 111
Study 26524699 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 111
Study 25516028 — intervention group
Group type: EXPERIMENTAL
Intervention: stretching+educational DVD
Number of subjects: 72
Study 25516028 — intervention group
Group type: COMPARATOR
Intervention: stretching+cognitive training
Number of subjects: 72
Study 25516028 — intervention group
Group type: COMPARATOR
Intervention: aerobic+educational DVD
Number of subjects: 72
Study 25516028 — intervention group
Group type: COMPARATOR
Intervention: aerobic+cognitive training
Number of subjects: 72
Study 22966414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Kaneka QH ubiquinol; 300 mg per day)
Number of subjects: 15
Study 22966414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19412016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable plate
Number of subjects: 40
Study 19412016 — intervention group
Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 40
Study 17218573 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg/d)
Number of subjects: 26
Study 17218573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17218573 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 26
Study 12838055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifty units per kilogram of recombinant human erythropoietin
Number of subjects: 45
Study 11156217 — intervention group
Group type: EXPERIMENTAL
Intervention: GMK vaccine (30 microg of G(M2)) and GDK (various doses)
Number of subjects: 31
Study 11156217 — intervention group
Group type: EXPERIMENTAL
Intervention: GDK (30 or 70 microg of G(D2))
Number of subjects: 31
Study 11156217 — intervention group
Group type: EXPERIMENTAL
Intervention: GDK (various doses)
Number of subjects: 31
Study 11156217 — intervention group
Group type: EXPERIMENTAL
Intervention: GDK (highest dose level)
Number of subjects: 31
Study 8891621 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 20
Study 8891621 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 20
Study 8891621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 80 mg
Number of subjects: 20
Study 2006355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 2006355 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 6625729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 X 40 mg kg‐1 (Group A)
Number of subjects: 431
Study 6625729 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 20 mg kg‐1 (Group B)
Number of subjects: 431
Study 6625729 — intervention group
Group type: COMPARATOR
Intervention: 1 X 40 mg kg‐1 (Camps)
Number of subjects: 431
Study 30106837 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) in VFO patients (n=91)
Number of subjects: 286
Study 30106837 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (started after 48 hours) in non-VFO patients (n=108)
Number of subjects: 286
Study 30106837 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (started after 48 hours) in VFO patients (n=88)
Number of subjects: 286
Study 31301057 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercise training (Group B)
Number of subjects: 45
Study 31301057 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise program (Group C)
Number of subjects: 45
Study 31301057 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy intervention strategies (Group A)
Number of subjects: 45
Study 28708216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) ceftazidime prior to colonoscopy (Group A)
Number of subjects: 93
Study 28708216 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Group B)
Number of subjects: 93
Study 26043222 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (participated in a football match)
Number of subjects: 34
Study 26043222 — intervention group
Group type: COMPARATOR
Intervention: Control group (participated only in measurements and practices)
Number of subjects: 34
Study 24201237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 65
Study 24201237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 21701528 — intervention group
Group type: EXPERIMENTAL
Intervention: TRA/TIM BAK-free
Number of subjects: 388
Study 21701528 — intervention group
Group type: COMPARATOR
Intervention: TRA/TIM
Number of subjects: 388
Study 19433694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 19433694 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 19433694 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study 19433694 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin mesylate
Number of subjects: 0
Study 16675323 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 50, 100, 200, and 400 microg/d, each for 7 days
Number of subjects: 14
Study 16675323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16124647 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN
Number of subjects: 60
Study 16124647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Green vegetables (4th quartile)
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomatoes
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Beans/lentils/nuts
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (3rd quartile)
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit (4th quartile)
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined-grain bread (4th quartile)
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain breakfast cereals
Number of subjects: 1253
Study 10578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptoxanthin (4th quartile)
Number of subjects: 1253
Study 8909626 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Talk intervention (multimedia, computer-based violence-prevention program)
Number of subjects: 558
Study 8909626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to SMART Talk during the intervention period)
Number of subjects: 558
Study 1812311 — intervention group
Group type: EXPERIMENTAL
Intervention: Health contract intervention
Number of subjects: 69
Study 6416861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-norgestrel (120 micrograms)
Number of subjects: 26
Study 6416861 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg)
Number of subjects: 26
Study 30880522 — intervention group
Group type: COMPARATOR
Intervention: Patient-selected music (Pandora®)
Number of subjects: 150
Study 30880522 — intervention group
Group type: COMPARATOR
Intervention: Preselected music (Mozart)
Number of subjects: 150
Study 30880522 — intervention group
Group type: EXPERIMENTAL
Intervention: No music (control)
Number of subjects: 150
Study 30778667 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% L-ascorbate-2-phosphate trisodium salt (APS) in test lotion (TL)
Number of subjects: 27
Study 30778667 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion (PL)
Number of subjects: 27
Study 29395188 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg daily for 3 weeks)
Number of subjects: 104
Study 29395188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 3 weeks)
Number of subjects: 104
Study 27872863 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine + methylphenidate
Number of subjects: 38
Study 27872863 — intervention group
Group type: COMPARATOR
Intervention: cetirizine
Number of subjects: 38